Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
2(18%)

Phase Distribution

Ph not_applicable
3
27%
Ph phase_1
1
9%
Ph phase_4
1
9%
Ph phase_2
5
45%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(3)
Completed(4)
Terminated(4)

Detailed Status

Completed4
Not yet recruiting3
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 25 (50.0%)
Phase 41 (10.0%)
N/A3 (30.0%)

Trials by Status

not_yet_recruiting327%
terminated218%
withdrawn218%
completed436%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11